Emergent BioSolutions upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Dana Flanders upgraded Emergent BioSolutions to Buy and raised his price target for the shares to $75 from $60.https://thefly.com/landingPageNews.php?id=2816267
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.